YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Vericel has delivered a solid 31.4% share price gain over the past year, which naturally puts a spotlight on whether that move lines up with the cash the business is expected to generate. With the stock last closing at US$39.71, the key is…
Vericel Corporation BURLINGTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present…
MediWound Ltd. EscharEx® Phase III VALUE Trial Advancing; Interim Assessment and Enrollment Completion Expected by End of First Quarter 2027 Master Services Agreement Signed with Vericel Under its BARDA Contract for NexoBrid® Second Quarte…
IPO Edge hosted a fireside chat with Conexeu Sciences Inc. (Nasdaq: CNXU) President and Chief Executive Officer Miles Harrison, moderated by IPO Edge Editor-in-Chief John Jannarone and Editor-at-Large Jarrett Banks in a video session lasti…
Key Points Interested in Vericel Corporation? Here are five stocks we like better. Record Q2 performance: Vericel's revenue rose 22% year over year to $77.5 million, while GAAP net income reached $2.2 million and free cash flow totaled $14…
Vericel Corporation (VCEL) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to a loss of $0.01 per share a year ago. These figures are adjusted for non-re…
Vericel Corporation Total Revenue Increased 22% to $77.5 Million, with MACI Revenue Growth of 23% Net Income of $2.2 Million and Free Cash Flow of $14.3 Million Full-Year 2026 Revenue Guidance Raised to $330 to $340 Million Board of Direct…
[Annual report under review] Willie B. Thomas In its Q2 portfolio update, Next Century Growth Investors disclosed nine new positions across three sectors. The industrial additions were Park Aerospace Corp. (PKE [https://seekingalpha.com/sy…
BURLINGTON, Mass., July 16, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its second quarter 20…
Vericel Corporation BURLINGTON, Mass., July 16, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report i…
Key Points 10,000 Common Stock shares were sold for a transaction value of $402,000 at an average price of around $40.24 per share on June 18, 2026. The sale represented 38% of Halpin's direct Common Stock holdings, reducing his direct sta…
Michael Halpin, Chief Operating Officer of Vericel Corporation (NASDAQ:VCEL), reported the sale of 10,000 shares of Common Stock for a transaction value of approximately $402,000 on June 18, 2026, as disclosed in a SEC Form 4 filing. Trans…
Issued on behalf of Conexeu Sciences Inc. A sector analysis of regenerative medicine — the science of restoring tissue rather than merely replacing it — and where a new generation of platform companies is trying to fit in. NEW YORK, June 1…
Vericel Corporation BURLINGTON, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present…
Soleus Capital Management disclosed a significant buy of Vericel(NASDAQ:VCEL), adding 1,785,079 shares in the first quarter—an estimated $63.40 million trade based on quarterly average pricing—according to a May 14, 2026, SEC filing. What…
Over the last 7 days, the United States market has risen 1.3% and over the past 12 months, it is up by an impressive 28%, with earnings forecasted to grow by 17% annually. In this robust environment, identifying high growth tech stocks inv…
Issued on behalf of Conexeu Sciences Inc. A biotech debut out of Reno is betting that the next wave of medicine won’t replace tissue — it’ll grow it back. NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- Energy Metal News News Commentary — Somew…
A week ago, Vericel Corporation (NASDAQ:VCEL) came out with a strong set of first-quarter numbers that could potentially lead to a re-rate of the stock. Results overall were solid, with revenues arriving 7.6% better than analyst forecasts…
Vericel Corporation (VCEL) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.23 per share a year ago. These figures are adjusted for non-recurring items.…
Vericel Corporation Total Revenue Increased 30% to $68.4 Million, with MACI Revenue Growth of 22% and Burn Care Revenue Growth of 91% Gross Margin of 72% and Adjusted EBITDA Growth of 195% Free Cash Flow of $15.1 Million Full-Year 2026 Rev…
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Silicon Laboratories Inc (Symbol: SLAB), where a total of 8,212 contracts have traded so far, representing approximately 821,200 u…
Vericel Corporation (VCEL) closed the last trading session at $35.57, gaining 4.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The m…
Vericel logo Key Points Shareholders elected seven directors: Dominick Colangelo, Alan Rubino, Heidi Hagen, Robert Zerbe, Kevin McLaughlin, Lisa Wright, and Paul Wotton were each elected to one-year terms expiring at the 2027 annual meetin…
In the last week, the United States market has stayed flat, but over the past 12 months, it has risen by 29%, with earnings expected to grow by 16% per annum in the coming years. In this context of robust growth expectations, identifying h…
Vericel Corporation CAMBRIDGE, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report i…
* Vericel (VCEL [https://seekingalpha.com/symbol/VCEL]) secured a 10-year contract [https://seekingalpha.com/pr/20461630-vericel-announces-barda-award-valued-at-up-to-197-million-for-procurement-and-advanced] worth up to $197M from the U.S…
MediWound Ltd. MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million YAVNE, Israel, April 2, 2026 — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics focused on…
Vericel Corporation CAMBRIDGE, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, has been awarded a ten-year contract valued at…
Over the last 7 days, the United States market has dropped 3.5%, yet it remains up by 14% over the past year with earnings forecasted to grow by 15% annually. In this dynamic environment, identifying high growth tech stocks requires a focu…
Madison Investments, an investment advisor, released its fourth-quarter 2025 investor letter for “Madison Small Cap Fund”. A copy of the letter can be downloaded here. The fourth quarter was challenging for the fund and continued to underp…
In early March 2026, Vericel Corporation reported that the FDA approved commercial manufacturing of its knee cartilage repair therapy MACI at the company’s Burlington, Massachusetts cell therapy facility, allowing production to begin there…
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Vericel received FDA approval for commercial manufacturing of MACI at its new Burlington facility. The approval allows…
Vericel Corporation (NASDAQ:VCEL) is one of the Best Small-Cap Growth Stocks to Buy According to Hedge Funds. On March 4, Vericel Corporation (NASDAQ:VCEL) announced securing a major win from the FDA. The company announced receiving FDA ap…
Vericel Corporation Company Achieves Significant Regulatory and Operational Milestone Substantially Increases Manufacturing Capacity to Support Long-Term Growth Enables Potential MACI Commercialization Outside of the U.S. CAMBRIDGE, Mass.,…
CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the following inv…
Vericel Corporation CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present…